

1/Pw

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/528951-Conf. #88756
	Int'l Filing Date	September 23, 2003
	First Named Inventor	Flockhart et al.
	Art Unit	N/A
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Attorney Docket Number	B0192.70057US00

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): References cited GB Search Report for GB 0222077.0 GB Search Report for GB 0322263.5 International Search Report for PCT/GB03/04078 Supplemental Application Data Sheet Return Receipt Postcard
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	WOLF, GREENFIELD & SACKS, P.C.		
Signature			
Printed name	John R. Van Amsterdam		
Date	July 19, 2006	Reg. No.	40,212

Certificate of Mailing Under 37 CFR 1.8(a)	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Dated: <u>July 19, 2006</u>	Signature: <u>Sylvana Householder</u> (Sylvana Householder)



DOCKET NO.: B0192.70057US00


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ian FLOCKHART, et al.
Serial No.: 10/528,951
Confirmation No.: 8756
Int'l Filing Date: September 23, 2003
Title: METHOD OF PREPARING CANNABINOIDS FROM PLANT MATERIAL

Examiner: Not yet assigned
Art Unit: 1743

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 19th day of July, 2006.


Sylvana Householder

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case.

No fee or certification is required.

II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

GB Search Report for Application No. GB 0222077.0 (copy enclosed).

GB Search Report for Application No. GB 0322263.5 (copy enclosed).

International Search Report for Application No. PCT/GB03/04078 (copy enclosed).

PART III: Explanation of Non-English Language References and Remarks Concerning Other Information Cited

The following is a concise explanation of the relevance of each non-English language reference listed on the attached form PTO-1449 (modified PTO/SB/08):

Please see Abstract for WO 02/32420 (Ref. B1).

Please see Abstract for JP 3153625 (Ref. B4).

Please see Abstract on page 187 of *Annales pharmaceutiques françaises* journal (Ref. C3).

PART IV: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.


Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,
Ian FLOCKHART, et al., Applicants


John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210
Telephone: (617) 646-8000

Docket No. B0192.70057US00
Dated: July 19, 2006
xNDDx



FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/528,951		DOCKET NO.: B0192.70057US00	
				INT'L. FILING DATE: 09/23/03		Confirmation No.: 8756	
				APPLICANT: Ian FLOCKHART, et al.			
				GROUP ART UNIT: 1743		EXAMINER: Not yet assigned	
Sheet	1	of	1				

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A1	*6,403,126	B1	Webster et al.	06-11-2002
	A2	*6,365,416	B1	Elsohly Mahmoud A. et al.	04-02-2002
	A3	*2002/086438	A1	Elsohly Mahmoud A. et al.	07-04-2002

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	B1	WO	02/32420	A1	DELTA-9-PHARMA-GMBH	04-25-2002	Abstract
	B2	WO	03/064407	A3	Resolution Chemicals Limited	08-07-2003	
	B3	WO	03/063847	A	GW Pharma Ltd.	08-07-2003	
	B4	JP	3153625	A	Tsumura and Co.	07-01-1991	Abstract

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C1	Lehmann T. et al., "A New Chromatographic Method for the Isolation of Levo-Delta-9-Trans Tetrahydrocannabinolic Acid A," <i>Phytochemical Analysis</i> , Vol. 3, No. 2, pgs 88-90 (1992)	
	C2	ODCCP, Bulletin on Narcotics, 1976, Issue 4 – 007, M. Reppeto et al., "Separation of Cannabinoids," pgs. 69-74	
	C3	Paris M. R. et al., "Isolation of 2 Constituents Cannabidiolic-Acid and Tetra Hydro Cannabinolic-Acid From Cannabis-Sativa by Preparative Thin Layer Chromatography," <i>Annales pharmaceutiques françaises</i> , vol. 31, no. 3, 1973, pgs. 186-188	Abstract only
	C4	R. Straight, et al., "Marihuana Extraction and Purification for Oral Administration of Known Amounts of Δ ⁹ -Tetrahydrocannabinol (THC)," <i>Biochemical Medicine</i> , vol. 8, pgs. 341-344, 1973	
	C5	Gaoni, et al., "The Isolation and Structure of Δ ¹ -Tetrahydrocannabinol and Other Neutral Cannabinoids from Hashish", <i>Journal of The American Chemical Society</i> , vol. 93: 217-224 (1971)	

EXAMINER	DATE CONSIDERED
----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*NOTE - The Office has waived the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications.]